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Will the crisis in
medical financing
lead to improved
“mileage” for our
health care efforts?
Medicine must be
personalized in
order to be effective
and cost-effective.
The opportunity for
medicine is to har-
ness the power of
technology, medical
informatics, genetics
and personalized
prevention, and
therapy for the best
outcome for our
patients.DITOR’S PAGE
risis
he economic crisis that the world is currently going through reminds me of the often-used
oot of the Chinese symbol for “crisis.” It is the symbol for “danger” plus the symbol for “op-
ortunity” or “resourcefulness.” Far be it for me to claim understanding of economic opportu-
ities in a markedly depressed economy. Nor do I fail to see the enormous hardship that is
esulting from this condition. I am told that 70% of the American economy is consumer
pending, that is, buying “stuff.” George Carlin had a wonderful bit about the need for bigger
nd bigger houses in order to have some place for our “stuff.” And, much of the world depends
n selling us “stuff” to keep their economies afloat. In medicine, we are more fortunate than
ost since much of what we do is not completely discretionary. Nonetheless, medicine is
learly taking its lumps, and hospitals and physicians are suffering.
So there is plenty of “danger,” but where is the “opportunity”? The fact that health care
osts in the U.S. far exceed any other country was an interesting statistic as long as the bills
ere being paid. Now there is an imperative to control costs. This is where “opportunity” be-
omes the operative word. Not until gas prices hit $4.00 a gallon did I consider dumping my
eloved 18-year-old, 8-cylinder car for a hybrid. Now that prices have moderated I still enjoy
he 49 miles/gallon city driving compared to the previous 19. Will the crisis in medical financ-
ng lead to improved “mileage” for our health care efforts? The new administration is looking
o prevention as a means to improve this efficiency, and such efforts are laudable. But, how do
mproved prevention methods impact those of us engaged in interventional medicine? It should
e obvious that prevention is now morphing into “medical intervention” whether it is defined
s primary or secondary after one of our interventions. It is also clear that much of the medical
ntervention is being applied by interventional cardiologists.
Science and technology have been at the heart of interventional cardiovascular medicine and
ust also drive medical intervention. Through clinical research, we have created an extensive
vidence base that is currently being enforced through various mechanisms, but does one-size
vidence fit all? It would be ludicrous to put a stent in every patient with angina without clear
vidence of what the treatment was to accomplish. On the other hand, it is an excepted core
easure to put every patient on some statin no matter what dose or effect is achieved. The
uggestion that everyone with an abnormal C-reactive protein needs massive statin therapy is
he one-size-fits-all concept that, along with direct-to-consumer advertising, drives medical
osts. Medicine must be personalized in order to be effective and cost-effective. As shown in
he second generation stent trials, future events will be driven by progression of disease, not
ailure of the stent. Through active medical management, the chance of recurrent events and
oorly reimbursed costs can be reduced. Attention to therapies appropriate to each patient’s
roblems, including selection for or against intervention, will be increasingly scrutinized. Ge-
etic identification of which patients will benefit from which therapies, and which patients will
ot, is increasingly possible for many conditions. In order to apply these valuable cost-effective
ethods, which will enable treatment of the right patients, a form of universal health coverage
ill be necessary. Denying insurance to genetically susceptible people must not be allowed if
he power of genetics is to be added to our armamentarium.
The imperative of controlling costs will certainly lead to uncomfortable decisions, but the
ra of “every therapy for everyone” is over. The opportunity for medicine is to harness the
ower of technology, medical informatics, genetics and personalized prevention, and therapy
or the best outcome for our patients. I do not think that the “danger” in this crisis is the ex-
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79inction of the cardiologist or the interventionalist, be-
ause we are best suited to apply personalized approaches
hat produce the optimal cost-effective therapy for our
atients. It will be crucial to document those results
hrough research in order to mobilize the allies needed to
chieve these goals. Hopefully the economy will improve
n the coming years. In the meantime, it will be a tragedy
f we do not take advantage of the current crisis to build a
etter system of health care.ddress correspondence to:
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